Mitek Systems, Inc. MITK
Mitek's board is entrenching against ASG's $10 cash bid (51% premium) despite a declining core business, departed leadership, and a chairman dumping his own stock below the offer price.
Thesis
Elliott, one of Mitek's largest holders, demands the board engage with ASG Technologies (an Elliott portfolio company) on its $10-per-share take-private proposal, which represents a 51% premium to the October 9 unaffected close. Mitek's standalone path is risky: roughly two-thirds of revenue depends on the secularly declining mobile check-deposit market, margins have deteriorated, the diversification push into identity verification faces well-scaled competition, and the company recently lost both its CEO and CFO. The board has entrenched itself by adopting a Section 382 'poison pill' (drawing an 8% stock decline) disguised as tax-asset protection despite under $15M of deferred tax assets. Chairman Bruce Hansen has been a heavy seller of his own shares at $8.66-$9.16 since November 2017, contradicting his public dismissal of ASG's $10 bid. Elliott also requests a waiver to acquire up to 14.9%.
SCQA
Mitek Systems is a small-cap mobile-capture software company whose core revenue depends on a secularly declining check-deposit market while it tries to pivot into competitive identity-verification adjacencies.
ASG Technologies has offered $10/share cash (a 51% premium) but Mitek's leaderless board refuses to engage, adopts a poison pill, and entrenches behind a chairman who has been dumping his own shares below the bid price.
Engage with ASG immediately, sign an NDA to permit customary diligence toward a binding bid, rescind the entrenchment posture, and grant Elliott a waiver to accumulate up to 14.9% beneficial ownership.
Certain, premium cash value of $10/share today versus a stock that has not closed at $10 in the past year and faces meaningful downside if M&A speculation evaporates.
The three reasons
- 1
ASG's $10 cash offer is a 51% premium to the unaffected price and exceeds standalone risk-adjusted upside
- 2
Two-thirds of revenue is tied to the secularly declining check-deposit market with deteriorating margins
- 3
Chairman Hansen sold 66% of his vested shares at $8.66-$9.16 yet calls a $10 bid inadequate
Primary demands
- Engage with ASG Technologies and enter an NDA to allow due diligence on its $10/share take-private proposal
- Stop the entrenchment posture and unwind the recently adopted Section 382 'poison pill'
- Grant Elliott a waiver from the 4.9% Ownership Limit to acquire up to 14.9% beneficial ownership
- Address board composition issues including over-boarded directors and lack of CEO succession planning
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Notable slides (3)
Notes
Plain text-only public letter from Jesse Cohn and Jason Genrich (Elliott) to Mitek's board. No charts, slides, or branding beyond Elliott's Times Roman letterhead. Notable rhetorical moves: (a) using Chairman Hansen's own insider sales at $8.66-$9.16 to undermine his rejection of a $10 bid, (b) parsing day-by-day stock reactions to argue the share price is held up only by deal speculation, (c) attacking the Section 382 rights plan as a disguised poison pill given <$15M of deferred tax assets, (d) calling out an erroneous Hansen statement on the Q4 call about timing of ASG's approach. Exhibit A is a formal waiver request to lift the 4.9% pill cap to 14.9% — does not constitute a disclosed current stake. ASG Technologies and Evergreen Coast Capital are Elliott affiliates; this is the rare hybrid where the activist is also the prospective acquirer.